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ABSTRACT
Corticotropinomas are characterized by a relative resistance to the
negative feedback action of cortisol on ACTH secretion. In this respect
there is a similarity with the clinical syndrome of cortisol resistance.
As cortisol resistance can be caused by genetic abnormalities in the
glucocorticoid receptor (GR) gene, we investigated whether the in-
sensitivity of corticotropinomas to cortisol is also caused by de novo
mutations in the GR gene.
We screened for the GR gene in leukocyte and tumor DNA from 22
patients with Cushing’s disease for mutations using PCR/single
strand conformation polymorphism analysis. In a previous study, we
identified 5 polymorphisms in the GR gene in a normal population.
These polymorphisms were used as markers for the possible occur-
rence of loss of heterozygosity (LOH) at the GR gene locus.
Except for 1 silent point mutation, we did not identify novel mu-
tations in the GR gene in leukocytes or corticotropinomas from these
patients. Of the 22 patients, 18 were heterozygous for at least 1 of the
polymorphisms. In 6 of these patients, LOH had occurred in the tumor
DNA. Of 21 patients examined for LOH on chromosome 11q13, only
1, with a corticotroph carcinoma, showed allelic deletion. As controls
we studied 28 pituitary tumors of other subtypes (11 clinically non-
functioning, 8 prolactinomas, and 9 GH-producing adenomas) and
found evidence for LOH in only 1 prolactinoma.
In six patients LOH was found at the GR gene locus (chromosome
5) in DNA derived from adenoma cells. Our observations indicate for
the first time that LOH at the GR gene locus is a relatively frequent
phenomenon in pituitary adenomas of patients with Cushing’s dis-
ease. This might explain the relative resistance of the adenoma cells
to the inhibitory feedback action of cortisol on ACTH secretion. The
specificity of the GR LOH to corticotropinomas supports this concept.
Somatic mutations of the GR are not a frequent cause of relative
cortisol resistance in these cells. (J Clin Endocrinol Metab 83: 917–
921, 1998)
CUSHING’S disease is caused by an ACTH-secreting pi-tuitary adenoma arising from corticotropic cells. The
adenomas are characterized by a relative resistance of the
tumor cells to the feedback inhibition by glucocorticoids
(GCs) on ACTH secretion (1, 2). The biological effects of
cortisol (and other GCs) are mediated by the glucocorticoid
receptor (GR), a member of the family of intracellular hor-
mone receptors (3). These receptors are characterized by a
three-domain structure: a carboxyl-terminal ligand-binding
domain with transcriptional activity, a central DNA-binding
domain, and an N-terminal domain essential for transcrip-
tion activation (3). The effects of GCs can be the result of
either DNA binding of the ligand-bound receptor or inter-
actions of the receptor with other proteins within the nucleus
(4). Mutations in the hormone-binding domain of the GR
gene have been described as the cause of familial glucocor-
ticoid resistance (5–8). In a recent study, Karl and co-workers
(9) screened the GR gene in patients who developed Nelson’s
syndrome after bilateral adrenalectomy for Cushing’s dis-
ease and found a heterozygous somatic frame-shift mutation
in one of four macroadenomas investigated.
In the present study, we analyzed the GR gene in leukocyte
and tumor DNA samples from 22 patients with Cushing’s
disease, using PCR/single strand conformation polymor-
phism (SSCP) analysis, to see whether somatic mutations in
the GR gene in tumor DNA were responsible for the relative
cortisol resistance of the corticotropic tumor cells. In a pre-
vious study (10), PCR/SSCP screening revealed 5 GR poly-
morphisms in a normal population. Sequence analysis led to
the disclosure of point mutations in the PCR fragments con-
taining exons II, IV, V, and IX, respectively. In two of these
polymorphisms (summarized in Table 1), the variant se-
quences occur with relatively high frequencies (exon V in
31.3% and exon IX in 13.7% of the investigated population).
This allowed us to use these polymorphisms as markers for
the possible occurrence of loss of heterozygosity (LOH) at the
GR gene locus. The patients investigated were a subgroup of
the patients studied by Buckley et al. (11), who were tested
for accumulation of p53. As there are reports that the mul-
tiple endocrine neoplasm-1 locus on chromosome 11q13 is
potentially involved in the pathogenesis of all types of pi-
tuitary adenoma (12), we also examined this region of the
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genome for LOH in this unselected cohort of corticotropi-
nomas (13).
Subjects and Methods
All 22 patients included in the study had clinical features of Cushing’s
syndrome and biochemical evidence of excessive cortisol production.
All failed to suppress with low dose (4 doses of 0.5 mg) dexamethasone.
With regard to the differential diagnosis, different definitions of sup-
pression with high dose (4 doses of 2 mg) dexamethasone suppression
tests were used (e.g. 17-hydroxycorticosteroid, urinary free cortisol, and
sometimes plasma cortisol values). The high dose dexamethasone test
does not allow us to distinguish precisely the sensitivity to dexameth-
asone among this group of 22 patients with histologically proven ACTH-
secreting pituitary adenomas.
Using PCR/SSCP we analyzed the GR gene in tumor and leukocyte
DNA samples from 22 patients with pituitary-dependent Cushing’s
syndrome due to surgically and histologically defined adenomas. All
patients were operated on by transsphenoidal selective adenomectomy.
Tumor samples were fixed in 10% formalin and embedded in paraffin.
Tumor DNA was extracted from slide material using standard methods
(13), with the benefit that the DNA originates from histologically defined
adenoma tissue and, therefore, is as homogeneous as possible. Leuko-
cyte DNA was extracted from peripheral leukocytes using standard
methods. Tumors were divided into categories according to invasive-
ness, based on the patients’ computed tomography and magnetic res-
onance imaging reports, as described by Bates et al. (13, 14). Grades 1 and
2 include microadenomas and macroadenomas without radiological
evidence of invasion, respectively. Grade 3 are macroadenomas with
local invasion. One patient (no. 5) was previously described (15). She had
a corticotropic carcinoma, with intracerebral metastases demonstrated
on magnetic resonance imaging scan and at autopsy (grade 4).
To investigate the specificity of the changes in the GR gene in cor-
ticotropinomas, we also studied 28 other pituitary adenomas (11 clin-
ically nonfunctioning, 8 prolactinomas, and 9 GH-secreting adenomas).
PCR/SSCP analysis of the GR gene
PCR amplification of the GR gene was carried out using primers
previously described by Koper et al. (10). Because of the very limited
quantity of DNA in the samples, PCR amplification was performed in
two steps. The first amplification was performed in a total volume of 20
mL containing leukocyte or tumor DNA solution, 6 pmol of each oli-
gonucleotide from four different primer pairs, 200 mmol/L of each
deoxy-NTP, 3 mmol/L MgCl2, 0.5 U AmpliTaq (Perkin-Elmer, Norwalk,
CT), 50 mmol/L KCl, and 10 mmol/L Tris (pH 8.3). A 1:300 dilution of
the primary PCR product was used as a template for a second PCR
amplification under the same conditions, using one primer pair in each
reaction. SSCP analysis of the PCR products was carried out using 0.5 3
mutation detection enhancement (MDE) polyacrylamide gels (J. T. Baker
Chemicals, Deventer, The Netherlands) in the presence or absence of 5%
glycerol at 4 C as described by Orita et al. (16). Each SSCP gel contained
samples from controls with the normal sequence and from controls with
each of the five GR gene polymorphisms previously described by Koper
et al. (10). DNA fragments displaying an abnormal migration pattern
during SSCP analysis were amplified with the same primers for direct
sequencing using a modified Sanger dideoxynucleotide chain termina-
tion method, described in detail by Karl et al. (7).
LOH on chromosome 11
PCR amplification was performed using primers spanning the mic-
rosatellite repeat at the PYGM locus (11q13). Primer sequences for the
amplification were 59-GGAATGCTGATTTCCAGGTT-39, and 59-CTGT-
CAGGTAGCAACTGACATC-39, respectively. PCR reaction conditions
were: primer annealing at 50–54 C for 2 min, primer extension at 72 C
for 2 min, denaturation at 94 C for 1 min, and final extension at 72 C for
5 min. Leukocyte and tumor PCR products were run adjacently on
8–10% nondenaturing polyacrylamide gels, fixed in 10% methanol-10%
acetic acid, and then incubated in 0.1% aqueous silver nitrate for 15 min.
After two brief washes in distilled water, products were visualized by
development in an aqueous solution of 1.5% sodium hydroxide and 0.1%
formaldehyde. Allelic loss is identified by a reduction in intensity of
more than 80% or the absence of one of the expected PCR products (13).
Results were reviewed independently by two observers, and allelic
deletion was only recorded if agreed upon by both. All samples in which
LOH was identified underwent repeat PCR amplification and gel elec-
trophoresis with identical results.
TABLE 1. Sex, age, tumor grading, possible loss of heterozygosity at the GR gene locus or chromosomes 9 and 11, and P53 staining in
corticotropinomas from 22 patients with pituitary-dependent Cushing’s disease
Patient no Sex Age (yr) Grade
Glucocorticoid receptor gene PCR fragment
Chromosome 11 P53
Exon II/1 Exon II/5 Exon V Exon IX
1 F 15 1 NI NI Retained Retained Retained Nuc C
2 F 50 2 NI Retained Retained Retained Retained Nuc D
3 F 44 1 NI NI Retained Retained Retained Nuc B
4 F 60 1 NI NI Retained Retained Retained Negative
5 M 39 3/4 NI NI NI Retained LOH Cyt D
6 F 50 2 NI NI LOH Retained Retained Negative
7 F 52 1 NI NI NI NI Retained Negative
8 F 40 3 NI Retained NI NI Retained Negative
9 F 28 2 NI NI LOH LOH Retained Nuc B
10 F 48 1 NI NI LOH Retained Retained Nuc D
11 F 13 1 NI NI Retained NI Retained ND
12 F 25 1 LOH NI LOH NI Retained Nuc C
13 F 57 3 NI NI NI NI Retained Negative
14 F 33 1 NI NI Retained NI Retained Negative
15 F 58 1 NI NI NI NI Retained Negative
16 F 37 2 NI NI Retained NI Retained Nuc A
17 F 22 1 NI NI Retained NI Retained Nuc A
18 M 28 1 NI NI LOH NI Retained Negative
19 F 26 1 NI NI NI NI ND ND
20 F 32 1 NI NI Retained Retained Retained Negative
21 F 1 NI NI Retained NI Retained Negative
22 F 23 1 NI NI LOH LOH Retained Cyt C
Grade: 1, Microadenoma; 2, macroadenoma, no invasion; 3, macroadenoma with invasion; 4, macroadenoma with intra/extracranial spread.
LOH, Loss of heterozygosity; NI, not informative; ND, not determined; retained, informative, no LOH. P53: Nuc, nuclear staining; Cyt,
cytoplasmic staining; A, 75–100%; B, 50–75%; C, 25–50%; D, ,25%.
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Results
Age, sex, and tumor grading of the 22 patients investigated
are shown in Table 1. There were 20 female and 2 male
patients, aged 13–58 yr. There were 3 invasive tumors, 4
macroadenomas without invasion, and 15 microadenomas.
Patient 18 showed a novel SSCP pattern in exon VI of both
tumor and leukocyte DNA. Direct sequence analysis showed
that the abnormal pattern was the result of a silent heterozy-
gous point mutation (GCA to GCG at codon 618, both coding
for an alanine in the receptor protein; data not shown). None
of the other DNA samples analyzed revealed novel SSCP
variants in the GR gene. The GR PCR fragments containing
the polymorphisms, as described previously (10), served as
markers for possible LOH in the present study. The poly-
morphism in the PCR fragment containing exon IV was not
present in these 22 patients. In 1 patient (no. 12), the poly-
morphism in PCR fragment exon II/1 was present in leu-
kocyte DNA. In the tumor DNA of this patient, however, the
polymorphism was absent. This suggests that in the tumor
the variant allele was lost (Table 1). The polymorphism in the
39-part of exon II (PCR fragment exon II/5) was present in 2
subjects (no. 2 and 8). The polymorphism was seen in both
leukocyte and tumor DNA, indicating that there was no LOH
in this part of the GR gene in these two subjects (Table 1).
Figure 1 shows the SSCP patterns of the polymorphism in
the PCR fragment containing exon V in controls (AA, ho-
mozygous for the normal allele; AB, heterozygous; BB, ho-
mozygous for the variant allele), together with the leukocyte
and tumor SSCP patterns from several patients. Taking pa-
tient 6 as an example, a difference in the SSCP pattern in
leukocyte and tumor PCR products from this patient was
observed. Leukocyte DNA showed pattern AB (heterozy-
gous), whereas tumor DNA revealed pattern AA, suggesting
that the variant allele was not present in the tumor. A total
of 16 patients showed SSCP pattern AB in leukocyte DNA,
6 of whom had an AA pattern in their tumor DNA, indicating
that in 6 of the 16 patients who were heterozygous for the
polymorphism in exon V, LOH occurred at this specific part
of the GR. Six other patients were homozygous in leukocyte
DNA (5 of them showed pattern AA and 1 showed pattern
BB), so the polymorphism was not informative in these pa-
tients with respect to LOH (Table 1).
With respect to PCR fragment exon IX, 10 patients were
heterozygous for the polymorphism (AB) in leukocyte DNA,
2 of whom showed LOH in the tumor (SSCP pattern AA;
Table 1). The 12 other patients showed the homozygously
normal pattern (AA) in leukocyte DNA, so a conclusion
about a possible LOH in this part of the GR gene could not
be reached in these patients.
It can be concluded that 6 patients show LOH at the GR
locus, 3 of them in PCR fragment of exon V (patients 6, 10,
and 18) and 2 of them in both exons V and IX (patients 9 and
22). Patient 12 shows LOH at the N-terminus of exon II and
at exon V. Overall LOH was identified in 6 patients, het-
erozygosity was maintained in 12 patients insofar as the
polymorphisms were informative in these patients, and 4
patients were completely uninformative.
Tumor grading in patients in whose tumor LOH for the GR
gene was found, showed that none of these tumors was
invasive (Table 1). Only one patient (no. 5) showed LOH on
chromosome 11 at the PYGM locus. This subject had a ma-
lignant corticotroph carcinoma and has been reported in
detail previously (14). All other Cushing’s adenomas exam-
ined (n 5 21) retained the PYGM allele at 11q13. Insofar as
the data on LOH were informative, tumors showing LOH for
the GR gene locus do not show LOH on chromosome 11.
Similarly, for chromosome 11 LOH, heterozygosity in the
informative parts of the GR gene was retained.
Of 11 clinically nonfunctioning pituitary adenomas, 6 were
heterozygous for the polymorphism in exon V (showing the
AB phenotype); none of these tumors showed LOH. Five
were heterozygous for the polymorphism in exon IX, 4 of
which also were heterozygous for the exon V polymorphism.
The tumors exhibited no LOH for exon IX. The polymor-
phisms II/I and II/5 were not present in the DNA from
leukocytes and the adenomas.
Of eight prolactinomas, three were heterozygous for the
polymorphism in exon V; one of these tumors showed LOH
(the AB pattern was changed into a BB pattern). Two of these
tumors were also heterozygous for the exon IX polymor-
phism without showing LOH. The II/I and II/5 polymor-
phisms were not present in the DNA from leukocytes and the
adenomas. Of nine GH-producing adenomas, two were het-
erozygous for the exon V and IX polymorphisms but showed
no LOH in the tumor, and one was heterozygous for the
polymorphism in exon IX without showing LOH. No II/1
polymorphisms were present in the DNA from leukocytes
and the adenomas; in one case the II/5 polymorphism was
present in the leukocyte DNA and remained present in the
adenoma DNA.
In conclusion, 23 of these 28 pituitary tumor types were
heterozygous for at least 1 of the polymorphisms investi-
gated, whereas LOH was detected only in 1 of them. Statis-
tical analysis using the Fisher exact test on LOH in the GR
gene in corticotropinomas vs. pituitary adenomas of other
origin showed P , 0.02.
Discussion
Hypercortisolism in Cushing’s disease is caused by semi-
autonomous ACTH secretion by a pituitary corticotropi-
noma, in most cases a microadenoma (17). Corticotropino-
mas are characterized by a decreased sensitivity of the tumor
cells to the negative feedback action of cortisol on ACTH
secretion (1, 2), which is mediated by the GR. Hormone-
bound GRs regulate the expression of glucocorticoid-respon-
sive genes by activating or repressing the transcription of
FIG. 1. SSCP patterns of the polymorphism in the PCR fragment
containing exon V in controls (AA, homozygous for the normal allele;
AB, heterozygous; BB, homozygous for the variant allele) together
with the leukocyte and tumor SSCP patterns from several patients.
P6 revealed pattern AA in the tumor DNA, which in this case rep-
resents the presence of one A allele.
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glucocorticoid-regulated genes by binding to positive and
negative glucocorticoid response elements (18). The POMC
gene has been shown to contain a negative glucocorticoid
response element.
With respect to the diminished sensitivity to the inhibitory
feedback action of cortisol, corticotropinomas show similar-
ity with the syndrome of cortisol resistance. This syndrome
is characterized by increased serum concentrations of cortisol
due to a decreased inhibitory feedback by cortisol on pitu-
itary ACTH production without the clinical stigmata of
Cushing’s syndrome. The increased ACTH production re-
sults in secondary overproduction of adrenal androgens and
mineralocorticoids (19). It has been demonstrated that mu-
tations in the hormone-binding domain of the GR gene result
in the syndrome of cortisol resistance in man (5–8). In the
present study we investigated by PCR/SSCP analysis
whether somatic mutations in the GR gene in ACTH-secret-
ing pituitary adenoma cells might be responsible for the
relative cortisol resistance observed in these tumors. In only
one patient (no. 18) was a silent point mutation in exon VI
identified (in both leukocyte and tumor DNA), indicating
that small de novo mutations in the GR gene in corticotropic
cells are not frequently involved in the relative cortisol re-
sistance of ACTH-secreting tumor cells in the pituitary. In a
recent paper also no point mutations in the GR gene were
found in 17 corticotropinomas, whereas additional studies
did not point to a differential relative expression of the two
GR isoforms (20).
We have recently described 5 polymorphisms in the GR
gene (10). These polymorphisms were used as markers for
the detection of LOH at the GR locus in these 22 cortico-
tropinomas. We found LOH in 6 of the 18 tumors in which
at least 1 of the polymorphisms was informative. In 4 cases,
no informative polymorphisms were present. Our data in-
dicate that the deletions that have occurred may be relatively
small. Thus, in tumors 6 and 10, LOH was found with respect
to exon V, whereas for exon IX, heterozygosity was retained.
Moreover, in patient 18, LOH in the tumor was found in exon
V, whereas the silent point mutation in exon VI was present
in both leukocyte and tumor DNA. For an adequate GC
response, all parts of the GR are essential. Deletions such as
those observed here will undoubtedly inactivate the gene
product if, indeed, any is made. Moreover, GR sensitivity has
been shown to be gene dosage dependent. Thus, Karl et al.
(7) described a family in which inactivation of 1 copy of the
GR gene, through a splice site mutation, resulted in reduced
GR number and glucocorticoid resistance. As the present
polymorphisms are located within the gene itself, and ob-
servations, such as in tumors 6, 10, and 18, suggest that
deletions might be relatively small, it is unlikely that these
results could have been reached using extragenic microsat-
ellite markers. LOH of the GR gene was found in 6 of the 18
informative corticotropinomas studied and in only 1 of the
23 informative nonfunctioning adenomas, prolactinomas,
and somatotropinomas. This does imply some specificity of
this LOH to corticotropinomas, making it more likely that it
contributes to the glucocorticoid resistance of this state.
From the data we obtained to date, it seems that adenomas
showing LOH at the GR gene locus are noninvasive tumors
that show no LOH on chromosome 11q13. Although this was
the only allele examined, the finding that the most frequent
allelic deletion in pituitary adenomas (12, 13) was not de-
tected here further supports the tumor subtype specificity of
GR LOH in corticotropinomas.
It would have been interesting to determine whether the
observed LOH at the GR gene locus is paralleled by reduc-
tions in the levels of GR messenger ribonucleic acid and GR
protein. Unfortunately, the nature (paraffin-embedded tis-
sues) and quantity of the material make extensive quantita-
tive studies at the protein and messenger ribonucleic acid
level impossible. Other studies have demonstrated that ho-
mozygous point mutations in the hormone-binding domain
of the GR gene cause the clinical syndrome of generalized
cortisol resistance in man (5, 6). The present data as well as
the results from these previous studies suggest that there
might be a decreased GR function in the pituitary tumors
from the six patients in whom LOH was demonstrated. Con-
sequently, these cells are relatively resistant to the inhibitory
feedback action of cortisol on ACTH secretion, which might
explain the increased ACTH production by these tumors.
Hypothesizing on the basis of the present data, the fol-
lowing model can be put forward. In a differentiated corti-
cotropic pituitary cell, a spontaneous genetic alteration, LOH
at the GR locus, occurs. Consequently, this cell is relatively
insensitive to cortisol. As the mutated corticotropic cell is less
sensitive to cortisol, this could be seen as a relative shortage
of inhibitory hormones, and it provides an advantage for
clonal selection, as previously proposed by Karl et al. (8). A
striking example of the enormous clonal expansion due to
discontinuation of the physiological inhibitory feedback by
cortisol is the Nelson tumor, which is an aggressive, fast
growing, ACTH-secreting pituitary adenoma. Nelson tu-
mors appear in 10–30% of patients who have previously
undergone bilateral adrenalectomy for Cushing’s disease. In
a recent study by Karl et al. (9), a somatic frame-shift mu-
tation in the GR gene was found in one of four Nelson tumors
investigated. It was concluded that the GR defect might have
played a pathophysiological role in the tumorigenesis of this
corticotropinoma. Another example in favor of the theory
that clonal expansion of a single genetically altered cortico-
tropic cell occurs as a result of diminished negative feedback
by cortisol is given by a patient described by Karl et al. (8).
This patient had cortisol resistance due to a dominant neg-
ative GR gene mutation. During the treatment for cortisol
resistance with low doses of dexamethasone, the patient
developed signs and symptoms of Cushing’s disease. De-
spite discontinuation of the dexamethasone treatment, the
symptoms of Cushing’s disease progressed. Eventually, the
patient underwent bilateral adrenalectomy, and subse-
quently, when a pituitary magnetic resonance scan became
positive for a tumor, a corticotropinoma was removed. It was
suggested that in this patient the exposure of the corticotroph
to enhance stimulation by increased production of hypotha-
lamic CRH and arginine vasopressin or a decreased sensi-
tivity of the corticotroph to the negative feedback by cortisol
may have led to adenoma formation.
From the data presented here it can be concluded that
simple somatic point mutations in the GR gene in cortico-
tropinomas do not seem to be the cause of the relative cortisol
resistance in these tumor cells. However, we demonstrate for
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the first time that there is a frequent loss of heterozygosity
at the GR gene locus in ACTH-secreting pituitary adenomas.
As deletion of (part of) the GR gene leads to glucocorticoid
resistance, this is a possible explanation for their relative
resistance to the inhibitory feedback of cortisol on ACTH
secretion. Furthermore, LOH at the GR gene locus may play
a pathophysiological role in the initiation of corticotropi-
noma formation, although our data are insufficient to relate
this to the size of the tumor.
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